When There’s a Will – There’s a Way
Our team is committed to improving the lives of cancer patients.
Introduction
Because GLIOBLASTOMA BRAIN cancer shouldn’t be a death sentence
Global Cancer Technology is a non-revenue biopharma company developing a novel treatment for cancers. We are developing a small molecule PI3K inhibitor that can cross the blood-brain barrier and has shown great promise in preclinical cell and animal studies as a potential glioblastoma therapy.
Glioblastoma Multiforme (GBM) is the most common form of brain cancer with an incidence rate of 3.21 per 100,000 population.
It is also the most malignant and aggressive form of brain tumor.
Most GBM’s have strong drug resistance against the PI3K/AKT/mTOR inhibitors due to the cytoprotective effect and the adaptive response of autophagy during the treatment.
Standard GBM treatments are toxic and associated with poor prognosis.
- Radiation can affect surrounding normal brain tissue
- Chemo has systemic adverse effects
Dr. Santosh Kesari
World-renowned Neuro-Oncologist-John Wayne Cancer Insitute
New Data! Glioblastoma Tumor Growth is Arrested
Our first anti-cancer inhibitor (patent pending) is currently in pre-clinical trials. Tumor growth in mice is arrested and the tumor appears to degrade based on the latest data.
- 15/052/526-Scintillating Nano-Crystals
- SD2013-199-, SD2016-342 "Wide field low dose irradiation to Activate an Ant-Tumor Pro-Drug carried by a Nano-vehicle", and "modification for improved PK"
The Problem
GBM's Unique Treatment Challenges
PI3K-AKT pathway is upregulated causing
Resistance to
- - Chemotherapy
- - Radiation
- - Immunotherapy
1
Suppression of
- - Immune Molecules
- - Lysosome Biogenesis
2
Activation of Microglia with the production of
- - Cytokines
- - Toxic Reactive Oxygen Species
3
Solution
OUR Solution: GCT-007
A unique, mechanistically distinct dual inhibitor targeting both the PI3K and mTOR pathways.
- Targets a novel PI3K pathway – autophagy
- Eliminates the problem of signaling blockade with conventional PI3K inhibitors by targeting more than one signaling protein
- Modulates immune cell function and inflammatory responses
- Crosses the Blood-Brain Barrier (BBB)
GCT-007 has thus far proven to:
- Induce Growth Arrest
- Increase Immune Recognition
- Increase Sensitivity to Radiation
Timeline
Research takes time and money. Bringing a drug to market now costs an average of $ 1.3 Billion and can take up to a decade in time. It is extremely challenging and with less funding, it can take even longer. Yet the potential to change lives makes it an attractive pursuit despite the complexity and risks.
Clinical Trial in Glioblastoma
Clinical Trial in Glioblastoma mid-
studies on the
inhibition of psoriasis.
Patent/Licenses/IP
GCT has acquired the right/license to the following the patents
- WO,2019,199874-Wo,2019,199864 for the glioblastoma drug
- Intellectual Property for whole blood Glioblastoma biomarkers
- 15/052/526-Scintillating Nano-Crystals
- SD2013-199-, SD2016-342 "Wide field low dose irradiation to Activate an Ant-Tumor Pro-Drug carried by a Nano-vehicle", and "modification for improved PK"
- Global Cancer Technology has recently filed a patent for using our GBM drug with checkpoint inhibitors